118 related articles for article (PubMed ID: 26412718)
1. To adhere or not to adhere: Rates and reasons of medication adherence in hematological cancer patients.
Hall AE; Paul C; Bryant J; Lynagh MC; Rowlings P; Enjeti A; Small H
Crit Rev Oncol Hematol; 2016 Jan; 97():247-62. PubMed ID: 26412718
[TBL] [Abstract][Full Text] [Related]
2. Prevalence and associated factors of medication non-adherence in hematological-oncological patients in their home situation.
Bouwman L; Eeltink CM; Visser O; Janssen JJWM; Maaskant JM
BMC Cancer; 2017 Nov; 17(1):739. PubMed ID: 29121889
[TBL] [Abstract][Full Text] [Related]
3. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed.
Eliasson L; Clifford S; Barber N; Marin D
Leuk Res; 2011 May; 35(5):626-30. PubMed ID: 21095002
[TBL] [Abstract][Full Text] [Related]
4. A review of factors influencing non-adherence to oral antineoplastic drugs.
Skrabal Ross X; Gunn KM; Suppiah V; Patterson P; Olver I
Support Care Cancer; 2020 Sep; 28(9):4043-4050. PubMed ID: 32335731
[TBL] [Abstract][Full Text] [Related]
5. Oral Chemotherapy in Patients with Hematological Malignancies-Care Process, Pharmacoeconomic and Policy Implications.
Betcher J; Dow E; Khera N
Curr Hematol Malig Rep; 2016 Aug; 11(4):288-94. PubMed ID: 27086140
[TBL] [Abstract][Full Text] [Related]
6. A mixed method study design to explore the adherence of haematological cancer patients to oral anticancer medication in a multilingual and multicultural outpatient setting: The MADESIO protocol.
Michiels S; Tricas-Sauras S; Dauvrin M; Bron D; Kirakoya-Samadoulougou F
PLoS One; 2021; 16(6):e0253526. PubMed ID: 34166438
[TBL] [Abstract][Full Text] [Related]
7. Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study.
Wu S; Chee D; Ugalde A; Butow P; Seymour J; Schofield P
Palliat Support Care; 2015 Apr; 13(2):255-63. PubMed ID: 24524212
[TBL] [Abstract][Full Text] [Related]
8. Exploring behaviors, treatment beliefs, and barriers to oral chemotherapy adherence among adult leukemia patients in a rural outpatient setting.
Lea CS; Bohra S; Moore T; Passwater C; Liles D
BMC Res Notes; 2018 Nov; 11(1):843. PubMed ID: 30497510
[TBL] [Abstract][Full Text] [Related]
9. Barriers to antiretroviral adherence in HIV-positive patients receiving free medication in Kayunga, Uganda.
Senkomago V; Guwatudde D; Breda M; Khoshnood K
AIDS Care; 2011 Oct; 23(10):1246-53. PubMed ID: 21939403
[TBL] [Abstract][Full Text] [Related]
10. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients.
Breccia M; Efficace F; Sica S; Abruzzese E; Cedrone M; Turri D; Gobbi M; Carella AM; Gozzini A; Usala E; Cavazzini F; Danise P; Tiribelli M; Binotto G; Pregno P; Bocchia M; Gaidano G; Crugnola M; Bonifacio M; Avanzini P; Celesti F; Guella A; Martino B; Annunziata M; Luciano L; Stagno F; Vallisa D; Pungolino E; Iurlo A; Rambaldi A; Nardiello I; Orlandi E; Gambacorti-Passerini C; Alimena G
Leuk Res; 2015 Oct; 39(10):1055-9. PubMed ID: 26282944
[TBL] [Abstract][Full Text] [Related]
11. Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review.
Banning M
Eur J Cancer Care (Engl); 2012 Jan; 21(1):10-9. PubMed ID: 22004071
[TBL] [Abstract][Full Text] [Related]
12. Oral antineoplastic agents: how do we care about adherence?
Barillet M; Prevost V; Joly F; Clarisse B
Br J Clin Pharmacol; 2015 Dec; 80(6):1289-302. PubMed ID: 26255807
[TBL] [Abstract][Full Text] [Related]
13. [Oral molecular targeting agents in hematological malignancy].
Wakabayashi S; Ohashi K
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1214-8. PubMed ID: 20647701
[TBL] [Abstract][Full Text] [Related]
14. Feasibility pilot on medication adherence and knowledge in ambulatory patients with gastrointestinal cancer.
Sommers RM; Miller K; Berry DL
Oncol Nurs Forum; 2012 Jul; 39(4):E373-9. PubMed ID: 22750908
[TBL] [Abstract][Full Text] [Related]
15. Adherence and patients' experiences with the use of oral anticancer agents.
Timmers L; Boons CC; Kropff F; van de Ven PM; Swart EL; Smit EF; Zweegman S; Kroep JR; Timmer-Bonte JN; Boven E; Hugtenburg JG
Acta Oncol; 2014 Feb; 53(2):259-67. PubMed ID: 24266637
[TBL] [Abstract][Full Text] [Related]
16. Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents.
Gebbia V; Bellavia G; Ferraù F; Valerio MR
Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S49-59. PubMed ID: 22149481
[TBL] [Abstract][Full Text] [Related]
17. A review on adherence management in patients on oral cancer therapies.
Wood L
Eur J Oncol Nurs; 2012 Sep; 16(4):432-8. PubMed ID: 22051845
[TBL] [Abstract][Full Text] [Related]
18. Conveying medication benefits to ulcerative colitis patients and effects on patient attitudes regarding thresholds for adherence.
Selinger CP; Kinjo Y; Jones DB; Katelaris P; Chapman G; McDonald C; Lal S; McLaughlin J; Robinson A; Leong RW
J Crohns Colitis; 2013 Sep; 7(8):e312-7. PubMed ID: 23219354
[TBL] [Abstract][Full Text] [Related]
19. The association between infections and chemotherapy interruptions among cancer patients: prospective cohort study.
Taha A; Vinograd I; Sakhnini A; Eliakim-Raz N; Farbman L; Baslo R; Stemmer SM; Gafter-Gvili A; Leibovici L; Paul M
J Infect; 2015 Mar; 70(3):223-9. PubMed ID: 25444974
[TBL] [Abstract][Full Text] [Related]
20. Medication Adherence: Truth and Consequences.
Brown MT; Bussell J; Dutta S; Davis K; Strong S; Mathew S
Am J Med Sci; 2016 Apr; 351(4):387-99. PubMed ID: 27079345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
